Compare MPLT & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MPLT | VALN |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 772.7M | 855.8M |
| IPO Year | 2025 | 2021 |
| Metric | MPLT | VALN |
|---|---|---|
| Price | $17.33 | $9.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $31.00 | $15.75 |
| AVG Volume (30 Days) | ★ 191.7K | 13.1K |
| Earning Date | 02-28-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $211,089,992.00 |
| Revenue This Year | N/A | $3.64 |
| Revenue Next Year | N/A | $12.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.48 |
| 52 Week Low | $12.24 | $5.17 |
| 52 Week High | $21.55 | $12.25 |
| Indicator | MPLT | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 46.41 | 44.46 |
| Support Level | $17.06 | $9.20 |
| Resistance Level | $19.34 | $10.09 |
| Average True Range (ATR) | 1.54 | 0.29 |
| MACD | -0.05 | -0.12 |
| Stochastic Oscillator | 31.57 | 13.90 |
MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.